Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration with emtricitabine/tenofovir-DF has not been studied. Based on metabolism and clearance a pharmacokinetic interaction with emtricitabine is unlikely. No clinically significant interaction was observed with tenofovir-DF (300 mg once daily) and fosamprenavir/ritonavir (700/100 mg twice daily). No dosage adjustment is necessary. A higher risk of renal impairment has been reported in patients receiving tenofovir-DF in combination with a ritonavir or cobicistat boosted protease inhibitor. Close monitoring of renal function is required in these patients.
A higher risk of renal impairment has been reported in HIV-1 infected patients receiving tenofovir disoproxil fumarate in combination with a ritonavir boosted protease inhibitor. Close monitoring of renal function is required in these patients. In HIV-1 infected patients with renal risk factors, the co-administration of tenofovir disoproxil fumarate with a boosted protease inhibitor should be carefully evaluated.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking